Remiges Ventures

About The Fund

Remiges Ventures is a venture capital firm headquartered in Far East Square, 32 Pekin Street #04-01, 049762, Singapore. The firm is dedicated to investing in various stages of company development, including seed-stage, early-stage, and later-stage companies, with particular focus on the healthcare, biotech, and life sciences sectors. Beyond this, they show a strong interest in medical devices, hospital services, oncology, and pharmaceutical industries. As a venture capital fund, they offer equity investments ranging from $10,000 to $5,000,000, with a sweet spot around $1,500,000 for their investments. Their expertise in startup growth through early and later funding stages, including Seed, Series A, and Series B, supports the advancement of their portfolio companies and fosters innovation in crucial healthcare solutions. Remiges Ventures manages assets worth approximately $80 million and operates with a vision to create value through strategic collaborations, research partnerships, and support for their portfolio companies' technological advancements. Some of their notable actions include a portfolio company, KisoJi Biotechnology, entering a strategic collaboration with Cancer Research UK, and another, Qinotto, initiating a collaboration with Lilly for neurodegenerative disease treatment solutions. Significant scientific contributions from their investments, such as significant research findings from LUCA Science published in Nature Metabolism, highlight their commitment to advancing medical science. Remiges Ventures also engages with the global community, evident from different language options such as Japanese available on their website, indicating an international reach and diversity in its business operations.